Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jen-Yu Hung

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
International Journal of Biological Sciences|September 17, 2025
Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung CancerYing-Ming Tsai, Jen-Yu Hung, Yu-Yuan Wu, et al.
Cancers|April 30, 2021
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung CancerCheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 26, 2020
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in TaiwanYuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, et al.
Cancers|April 13, 2023
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with <i>EGFR</i>-Mutant Advanced Lung Adenocarcinoma Treated with First-Line AfatinibMing-Ju Tsai, Jen-Yu Hung, Juei-Yang Ma, et al.
Hepatology International|December 1, 2021
Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)Jee-Fu Huang, Ming-Yen Hsieh, Yu-Ju Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencingYen-Ting Lin, Chi-Lu Chiang, Jen-Yu Hung, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysisCaicun Zhou, Ke-Jing Tang, Baogang Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU StudyMelissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
Cell|August 19, 2007
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathwayDung-Fang Lee, Hsu-Ping Kuo, Chun-Te Chen, et al.
The New England Journal of Medicine|October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 InsertionsCaicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
International Journal of Biological Sciences|September 17, 2025
Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung CancerYing-Ming Tsai, Jen-Yu Hung, Yu-Yuan Wu, et al.
Cancers|April 30, 2021
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung CancerCheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 26, 2020
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in TaiwanYuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, et al.
Cancers|April 13, 2023
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with <i>EGFR</i>-Mutant Advanced Lung Adenocarcinoma Treated with First-Line AfatinibMing-Ju Tsai, Jen-Yu Hung, Juei-Yang Ma, et al.
Hepatology International|December 1, 2021
Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)Jee-Fu Huang, Ming-Yen Hsieh, Yu-Ju Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencingYen-Ting Lin, Chi-Lu Chiang, Jen-Yu Hung, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysisCaicun Zhou, Ke-Jing Tang, Baogang Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU StudyMelissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
Cell|August 19, 2007
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathwayDung-Fang Lee, Hsu-Ping Kuo, Chun-Te Chen, et al.
The New England Journal of Medicine|October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 InsertionsCaicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.
Pageof 14